European pharmaceutical journals: Relationship between demand and indexation - the example of the main French document supplier
Pascal Bador, M. Ben Romdhane, T. Lafouge

To cite this version:

HAL Id: sic_00161077
https://archivesic.ccsd.cnrs.fr/sic_00161077
Submitted on 9 Jul 2007

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.
European pharmaceutical journals: Relationship between demand and indexation - the example of the main French document supplier

Pascal Bador¹²³, Mohamed Ben Romdhane², Thierry Lafouge².

¹Centre de Documentation Pharmaceutique
ISPB-Faculté de Pharmacie - Université Claude Bernard Lyon 1
8, avenue Rockefeller
F-69373 Lyon cedex 08 - France.

²Laboratoire Recodoc
Université Claude Bernard Lyon 1, Bat 721
43, boulevard du 11 novembre 1918
F-69622 Villeurbanne cedex, France.

³Author to whom all correspondence should be addressed (e-mail: pascal.bador@univ-lyon1.fr)

Summary

The purpose of the study was to analyse the way in which papers published by European pharmaceutical journals are made available by the main French document supplier, “Institut National de l’Information Scientifique et Technique” linked to the “Centre National de la Recherche Scientifique” (INIST-CNRS).

After having given a definition and built up a sample of 289 journals, orders for them during 1996-1999 were analysed. Then, the possible relationships between orders to INIST-CNRS and the impact of journals on the scientific community (from Institute for Scientific Information (ISI) data) were examined. Finally, a study was made of relationships between document orders to INIST-CNRS and the indexation of European pharmaceutical journals in bibliographic databases.

Key words

journal, pharmacy, Europe, document supplier

Résumé

Notre travail avait pour objectif d’analyser le processus de fourniture d’articles publiés dans les périodiques pharmaceutiques européens, par le principal fournisseur de documents qu’est l’Institut National de l’Information Scientifique et Technique lié au Centre National de la Recherche Scientifique (INIST-CNRS).


Enfin, nous avons étudié les relations existant entre les commandes de documents à l’INIST-CNRS et le signalement des périodiques pharmaceutiques européens dans les bases de données bibliographiques.

Mots Clés

périodique, pharmacie, Europe, fournisseur de documents
European pharmaceutical journals: Relationship between demand and indexation - the example of the main French document supplier

Introduction

In the pharmaceutical field, as for most scientific disciplines, journals remain the fundamental means of publication and disclosure of research findings. Journals also make it possible to publish reviews, and articles providing on-going education and regular information for professional pharmacists.

Access to articles published in journals is obtained naturally by direct readers subscriptions. However, in view of the number of journals (estimated at about 25,000 for the biomedical field), it is simply impossible for professionals to subscribe to all the journals in which they might be interested, even within a narrow range of activity. This becomes even more evident when the subscription prices of the majority of journals are taken into account, since these generally range from $150 to $5000.

All professionals, whether practitioner, industrial or research pharmacists, will therefore necessarily on some occasion need access to articles available from other document suppliers. These basically consist of public or private information centres, university libraries and the “Institut National de l’Information Scientifique et Technique” linked to the “Centre National de la Recherche Scientifique” (INIST-CNRS) in France and the British Library in the United Kingdom.

This article therefore offers an analysis of the way in which articles published by European pharmaceutical journals are made available by the main French document supplier, the INIST-CNRS. After giving a definition and creating a representative sample of these journals, orders for articles from them during 1996-1999 will be analysed. Then, the possible relationships between orders to INIST-CNRS and the impact of journals on the scientific community (from Institute for Scientific Information (ISI) data) will be examined. Finally, a study will be made of relationships between orders to INIST-CNRS and the presence of European pharmaceutical journals in bibliographic databases.

1. Context of the study

1.1 INIST-CNRS, principal French document supplier

The purpose of the INIST-CNRS is to collect, process and diffuse the results of scientific and technical research in France and other countries. Documents collected by the INIST-CNRS cover most scientific and technical research in the world: 27,000 international journals, conference proceedings, grey literature, and so on. To give an idea of the scale, it is to be noted that nowadays the INIST-CNRS supplies 700,000 photocopies of documents per year. The INIST-CNRS supplies two multilingual and multidisciplinary bibliographic databases: Pascal for science, technology and medicine, Francis for human and social sciences.
1.2 Creation of the sample of European pharmaceutical journals

This study is a follow-up to work already done on European pharmaceutical journals (Badar, Picard and Locher, 1994), to work concerning pharmaceutical journals in French (Bador, Grand and Locher, 1996, 74-81; Bador, Grand and Locher, 1996, 131-140), and to a study on evaluation of the quality of pharmaceutical journals (Bador and Petit, 1998). The definition of “European pharmaceutical journal” given in article of Bador, Picard and Locher (1994) is therefore retained and adapted.

Thus, for this present study a “European pharmaceutical journal” is considered to be a journal with all of the following characteristics:
- published by a European organisation or publisher, that is to say with at least one agency and an address in Europe,
- publishing articles intended to inform or educate practitioner, hospital, industrial or research pharmacists,
- dealing with pharmacology or pharmacy in the strict sense of these terms, that is to say dealing with allopathic medicines or activities ranging from conception to post-marketing follow-up studies, but excluding related sciences which constitute separate disciplines (biology, chemistry, physiology, haematology, immunology, cosmetology, homeopathy, toxicology, microbiology, dietetics, nutrition, etc.)

The sample of the 1993 article (Bador, Picard and Locher, 1994), consisting of 318 journals, was taken as starting point. Firstly, closed journals since 1993 have been eliminated, then newest journals have been added. So, a sample of 289 European pharmaceutical journals has been constituted for our study. These journals only meet the qualitative criteria above. They did not meet quantitative criteria from ISI such as number of citations, impact factor and so on.

1.3 Characteristics of the sample

Out of the 289 journals of the sample, 125, or 43.3%, are international journals, 98, or 33.9%, are national journals, the remaining 66 journals, or 22.8%, being difficult to define.

Out of these 289 journals, 130, or 45%, are scientific journals, 39, or 13.5%, are professional journals, 55, or 19% are mixed, both scientific and professional in character, and the remaining 56, or 22.5%, are difficult to classify. It is to be noted that all of the international journals, apart from two exceptions, are scientific journals.

Out of the 289 journals, 227, or 80%, come from seven countries, namely the United Kingdom, France, Germany, Spain, Switzerland, Italy and the Netherlands.

Data were supplied by the INIST-CNRS concerning the circulation of the journals during the four consecutive years 1996, 1997, 1998 and 1999. It is clear that journals themselves did not circulate but photocopies of articles from the journals which were ordered to the INIST-CNRS. Each journal was therefore classified according to the number of orders during these four consecutive periods.

Furthermore, these data were compared to the impact of these journals from the point of view of the rate of citations (data collected in the JCR	extsuperscript{3}). The data supplied by the INIST-CNRS were also compared to those concerning indexation of these journals in the bibliographic databases selected for the purposes of this study.

Out of the 289 journals of the sample, 153, or 52.9%, are at the INIST, and 60, or 20.7%, at the ISI.

The sample was divided into three groups according to orders from the INIST-CNRS:
- Group 1: the five journals most often ordered (over 1500 orders)
- Group 2: the other journals ordered, i.e. 144
- Group 3: the journals never ordered, i.e. 140.

The principal characteristics of the journals of these three groups are as follows:

**Group 1**
Out of the five journals in Group 1, all are to be found at the INIST-CNRS, all are present at the ISI.
Group 2
Out of the 144 journals in this group, 129, or 89.6%, are to be found at the INIST-CNRS, 55, or 38.2%, are present at the ISI.

Group 3
Out of the 140 journals in this group, 19, or 13.6%, are to be found at the INIST-CNRS, none is present at the ISI.

In order to obtain a better understanding of the indexation of these journals, the extent to which they were covered in the bibliographic data bases was studied.

Presentation of the data bases studied
The six most representative bibliographic data bases were selected, being the most easily accessible and the most widely consulted:

- Index Medicus/Medline, a specialised biomedical bibliography. This system is produced by the National Library of Medicine in the United States and indexes approximately 3100 journals (of which 74 European Pharmaceutical journals).
- Excerpta Medica/Embase, also a specialised biomedical bibliography. It is diffused by the publisher Elsevier in the Netherlands and indexes approximately 3500 journals (of which 119 European Pharmaceutical journals).
- International Pharmaceutical Abstracts/IPA, a specialised bibliography for pharmaceutical science. It is published by the American Society of Health-System Pharmacists (ASHP) in the United States and indexes approximately 800 journals (of which 119 European Pharmaceutical journals).
- Chemical Abstracts, a specialised bibliography for chemistry. It is published by the American Chemical Society in the United States and indexes approximately 10,000 journals (of which 124 European Pharmaceutical journals).
- Biological Abstracts/Biosis, a specialised bibliography for biology. It is published by the Biosciences Information Service in the United States and indexes approximately 9000 journals (of which 81 European Pharmaceutical journals).
- Current Contents, a bibliography of multidisciplinary summaries. It is published by the Institute for Scientific Information (ISI) in the United States and indexes approximately 2200 journals in the fields of life sciences and health (of which 61 European Pharmaceutical journals).

2. Analysis of orders for articles from European pharmaceutical journals at the INIST-CNRS

This analysis takes into account the orders for the articles from our sample journals. The numbers of orders for the last four consecutive years are:

Number of orders 1996  16930
Number of orders 1997  16723
Number of orders 1998  17047
Number of orders 1999  16525

Firstly, indices of linear correlation for each pair of years for orders from the INIST-CNRS were calculated, in order to find out if demand differed significantly from one year to another.

The following results were obtained:
• Orders 96 /97: index of linear correlation = 0.98
• Orders 97/98 : index of linear correlation = 0.98
• Orders 98/99 : index of linear correlation = 0.99

In order to compare the demand in 1998 and 1999, the two order distributions were closely analysed. These are given in the classical form of rank/frequency, then adjusted by the logarithmic model:
Frequency = -A.Log(rank)+ B  A>0 and B>0

The results obtained are shown in Figures 1 and 2 below:
The result of this adjustment shows the two distributions to be identical.

Moreover, in both cases the five journals most frequently ordered are the same. All of these considerations clearly demonstrate a stable demand for this sample of journals during these four years.

Once it was observed that the two distributions of orders in 1998 and 1999 presented the same characteristics, studies were made of the total orders for 96-97-98 (see Figure 3) and also of the number of orders in 1998. The essential characteristics of this demand over these three years are as follows:
- The total number of orders for articles is 50,700,
- The five most frequently ordered journals account for 24% of the demand, the ten most frequently ordered for 40%,
- 42 journals, or 28%, account for 80% of the demand,
- 146 journals, or 50%, were ordered at least once between 1996 and 1998.

Figure 3 below shows the numbers of requests per journal classified in decreasing order. This distribution is in accordance with the classical laws of bibliometrics, which are commonly observed in studies of the processes of circulation of documents (Salaun, Lafouge and Boukacem, 2000) where a small number of journals is sufficient to supply orders. This confirms the famous 80/20 rule – 80% of orders concern 20% of periodicals – (Burrell, 1985) which is customarily observed for distributions in libraries.

It is interesting to note that more than 70% of the orders for these European pharmaceutical journals emanate from companies. The INSERM ("Institut National de la Santé et de la Recherche Médicale": National Institute for Health and Medical Research) and the CNRS are the next two leading customers, with 7.7% and 4.4% of orders, respectively. The remaining 18% of orders mainly emanate from hospitals and universities. This observation appears logical inasmuch as the largest part of pharmaceutical research is carried out in industrial pharmaceutical laboratories, which are enormous and highly dynamic private-sector companies. So, in France pharmaceutical research expenditure is essentially self-financed by companies and public financing is less than 1%. Moreover, pharmaceutical industry is the industrial sector which dedicate to research and development the most important budget (Syndicat National de l’Industrie Pharmaceutique, 2002). This result accentuates the tendency observed for all the orders from the INIST-CNRS made during the month of January 1997 where approximately 45% of orders (in this case for all scientific fields) were made by companies (Salaun, Lafouge and Boukacem, 2000).

Out of the 144 journals ordered at least once from the INIST-CNRS (Group 2), 89, or 61.8%, are international journals, 31, or 21.5%, are national journals, 21, or 14.6% were not defined. Out of these 144 journals, 91, or 63.2%, are scientific journals, 8, or 5.6%, are professional journals, 22, or 15.3%, are scientific and professional journals.

Finally, out of the 140 journals which were not ordered from the (Group 3), 32, or 22.9%, are international journals, 67, or 47.9%, are national journals. Out of these 140 journals, 35, or 25%, are scientific journals, 31, or 22.1%, are professional journals, 33, or 23.6%, are scientific and professional journals. The majority being national or professional journals, we can think that readers have their own subscription and do not need to order their articles to INIST-CNRS.
3. **Relationships between orders and the impact of journals on the scientific community**

3.1 **Comparison between orders from INIST and indexation by ISI**

The preceding analysis showed that half of the journals of the sample were ordered from INIST-CNRS. Table I, below, gives the proportion of journals analysed by ISI and ordered from INIST-CNRS.

"Insert table I"

Out of the 289 journals of the sample, only 60 are indexed by ISI, which gives a coverage rate of 21%. This rate is high inasmuch as all the journals in the sample are European. It is important to note that:
- all these 60 journals are ordered from the INIST-CNRS,
- 87.5% of orders are requested from these journals.

These remarks seem to indicate that there might be a relationship between indexing in ISI and orders from the INIST-CNRS.

If we look at the orders for these European pharmaceutical journals emanating from companies, we observe the same trend (about 90% of orders concerned the 60 journals indexed by ISI).

Next, a finer analysis was attempted, of the relationship between the impact of the journals on the scientific community and the orders for them from the INIST-CNRS. Only the 60 journals analysed by the ISI are taken into account in the following calculations. The list of these 60 journals together with their principal characteristics is given in Appendix 1.

3.2 **Correlation between orders from INIST and JCR data**

In this part, the question is whether there is a correlation between orders from the INIST-CNRS and the data produced by the ISI. Among the indicators offered by the JCR, the number of citations was selected. The number of citations is relative to journals and not to articles. So, it is well known that one journal may have a high number of citations which is the result from the frequent citations of a very low number of articles. The phenomena has been well studied in scientometry (Garfield, 1998). Our intention here does not take into account this phenomena. We worked on orders of journals and here also a low number of frequently ordered articles of one journal may be at the root of a high number of orders of this journal. For confidentiality reasons, we did not have access to the titles of the ordered articles.

We study here the correlation between orders and the number of citations. For this purpose, 1998 orders and 1997 citations were selected (Figure 4).

"Insert figure 4 “

The correlation index is 0.63 for all of the 60 journals ordered from the INIST-CNRS. There is a significant correlation. At the signification threshold of 0.1% and for a number of 60 degrees of freedom, the test of r gives a theoretical correlation of 0.408.

For Group 1, the correlation is –0.46. There is therefore no correlation. We can observe that these five leading journals are on the periphery of the scatter plot (see Figure 4).

A detailed study shows us that the three journals Biochemical Pharmacology, European Journal of Pharmacology and British Journal of Pharmacology are both the most highly cited according to ISI and ordered from the INIST-CNRS. These journals are really important in pharmacology which is the main discipline in pharmacy. So, a very great number of researchers in companies and public institutions are interested in these prestigious pharmacological journals and will be likely to order copies of their articles. Moreover, these journals are very frequently published (European Journal of Pharmacology is published 52 times per year which gives about 800 articles, British Journal of Pharmacology is published 24 times per year which gives about 600 articles, Biochemical Pharmacology is published 24 times per year which gives about 400 articles) which leads to a very great number of articles being potentially both cited and ordered.
On the other hand, the two other journals of Group 1, International Journal of Pharmaceutics and Drugs are not very much cited according to ISI in relation to their very high number of orders from the INIST-CNRS. We can explain this phenomena by the fact that International Journal of Pharmaceutics publishes articles about pharmaceutical formulation and production for which researchers have a very little number of journals. So in this field, orders of articles are concentrated in these few journals. Moreover, International Journal of Pharmaceutics is frequently published (24 times per year which gives about 400 articles) and is very expensive (annual institutional subscription rate is about $6400). So, copies of the articles of this journal are very often ordered because a very little number of institutions can subscribe it. Finally, as seen in part 2, pharmaceutical companies which represent the great majority (70%) of the demands of articles are very interested in the field of pharmaceutical formulation (manufacturing process of tablets, capsules, perfusions, syrups...) which is the step just before the marketing of drugs. For the fifth journal, Drugs, the explanation is different in that the small number of citations, in comparison with the other journals of Group 1, is due to the fact that this journal is not frequently published (15 times per year). So, the number of articles published is much less important (200) which explains that they are less cited than articles of the four other journals of Group 1. This trend is confirmed by the fact that the impact factor of Drugs (about 4) is higher than the impact factor of the other four journals (from 1 to 3,7).

In the pharmaceutical field, and for our sample, it is clear that there is a relationship between orders from the INIST-CNRS and the number of citations given by ISI.

4. Relationships between orders for journals from the INIST-CNRS and their indexation in bibliographic databases

4.1 Indexation of journals in bibliographic databases

It can be seen that the bibliographic databases (see 1.3) which index the highest numbers of European pharmaceutical journals as defined in this study are IPA (120/289, or 41%), Chemical Abstracts (124/289, or 43%) and Embase (119/289, or 41%), well ahead of Biosis (81/289, or 28%), Medline (74/289, or 26%) and Current Contents (61/289, or 21%). These results seem logical since IPA, by definition, is a specifically pharmaceutical database, and it is well-known that Chemical Abstracts covers the pharmaceutical sector very widely. Even though these databases are of American origin (apart from Embase), it can be seen that European journals are certainly not under-estimated. Moreover, it can be seen that Embase, as a European database, largely and logically outclasses Medline for indexation of these journals.

Furthermore, it can also be seen that at least two-thirds of the European pharmaceutical journals listed in each of the bibliographic databases taken into account in this study are ordered from the INIST-CNRS.

The first three databases, which logically supply the highest number of titles ordered from the INIST-CNRS, compared to all of the 149 journals (Groups 1 and 2), are also Embase (101/149, or 68%), Chemical Abstracts (94/149, or 63%) et IPA (77/149, or 52%). This confirms that the INIST-CNRS possesses a stock of documents which corresponds well to these bibliographic databases which are widely used by researchers, and which is summed up in the graphs below.

The two figures 5 and 6 present, in percentages, to make the comparison easier, the two breakdowns arising from the above. There is a correspondence between the coverage of the journals in the databases and the orders from the INIST-CNRS.

“Insert figure 5 and figure 6”

Conversely, if consideration is given to the percentage of journals in these databases which are ordered from the INIST-CNRS, those listed by Current Contents (56/61, or 92%), Medline (64/74, or 86%) and Embase (101/119, or 85%) are proportionately more often ordered from the INIST-CNRS. This shows that these three databases concentrate their indexations on the most significant journals.
The five journals most frequently ordered from the INIST-CNRS (Group 1) are taken into account by all of the databases, except for the IPA database which lists only three out of five. This does indeed confirm that these journals are fundamental for the pharmaceutical field.

Concerning the coverage of the journals of Group 2 by the bibliographic databases, here again two categories can be distinguished: the first category consisting of the bibliographic databases which list more than 50% of the 144 journals ordered at least once from INIST-CNRS (Embase 96/144, or 66.7%, Chemical Abstracts 89/144, or 61.8% and IPA 74/144, or 51.4%); the second category those which list less than 50% of the journals ordered at least once from INIST (Medline 61/144, or 42.4%, Biosis 59/144, or 41.0% et Current Contents 51/144, or 35.4%).

Concerning the bibliographic coverage of the journals of Group 3, IPA (43/140, or 30.7%), Chemical Abstracts (30/140, or 21.4%) and Embase (18/140, or 12.9%) still cover the highest number and thereby demonstrate once again their good coverage of European pharmaceutical journals.

4.2 Relationship between indexation of journals in bibliographic databases and orders from the INIST-CNRS

In order to study this relationship, a count was made of the number of bibliographic databases (from 0 to 6) in which each journal is indexed. In order to know if, for the 149 journals ordered to the INIST-CNRS, there is a relationship between orders and indexation in databases, we first studied the correlation, as in part 3.2, between number of orders and number of indexations in bibliographic databases. There was no correlation. So, we proceeded differently. The 149 periodicals were classified according to the number of indexations in the databases. Then for each value (see Table II) the average number of orders for each category of journals was calculated.

“Insert table II”

“Insert figure 7”

The histogram of figure 7 shows a group of 43 journals indexed in five or six databases, which have a high number of orders. Thirty eight journals out of these 43, or 88%, are journals indexed by the ISI (see Appendix 1), which is not surprising because we know that 87.5% of orders come from the 60 journals of our sample indexed by the ISI (see table I). All these journals are at least one time indexed in one of the six bibliographic databases (see Appendix 1). It must be noted that 22 journals (out of the 60 indexed by the ISI), or 37%, are indexed in four or less than four databases. These two results confirm the predominance of the ISI.

Conclusion

This study shows that there is a possible relationship between impact of the European pharmaceutical journals, as measured by ISI’s Journal Citation Reports, and the number of orders from the INIST-CNRS. We have observed that the bulk of the orders or article copies comes from pharmaceutical private laboratories which represent the industrial sector dedicating the most important budget to research in France. So, public financing being less than 1% of all pharmaceutical research financing, this well confirms that pharmaceutical research is not being driven by disinterested academic researchers. This link was previously observed in the case of another important European document supplier, the British Library (Scales, 1976) and more recently at the INIST-CNRS (Salaun, Lafouge and Boukacem, 2000) but in both these cases the sample selected consisted of the 50 most frequently ordered documents.

The link found in this present study is the more significant in that the constitution of the sample of journals analysed is European and thematic. A priori, the constitution of the sample was independent of the selections made by the INIST-CNRS and by the ISI, and the results analysed are unbiased.

The indexation of European pharmaceutical journals indicates that the present sample is well covered by the large bibliographic databases and that the INIST-CNRS has a document stock which corresponds to these.
Without going so far as to say that the present sample is representative, it is well indexed in the great pools, meaning both the document suppliers and the databases. However, although demand and indexation are linked, citation and indexation are not, the logic here being different. To extend this study three directions would be interesting:
- work with editors as the basic entity, instead of individual journals,
- study orders at the level of interlibrary loan,
- extend our research to the corresponding pharmaceutical e-journals.

1 INIST-CNRS : 2 allée du Parc de Brabois, 54514 Vandœuvre-lès-Nancy Cedex. 
Web : http://www.inist.fr

2 JCR : Journal Citation Reports of the Science Citation Index produced by the Institute for Scientific Information (ISI). Web : http://www.isinet.com/

Acknowledgements

The authors wish to thank the team of the INIST-CNRS for supplying these data and for his support. Many thanks also to the GRESI team of the ENSSIB for the interest they have shown in this work.
References

BADOR P., GRAND C., LOCHER F.
La presse pharmaceutique francophone en 1995. II.. Liste et caractéristiques des périodiques pharmaceutiques francophones.

BADOR P., PICARD A., LOCHER F.

BADOR P., PETIT. O.
Facteur d’impact et indexation dans les bases de données bibliographiques : Comparaison de ces deux critères de qualité pour l’évaluation des périodiques pharmaceutiques,

BADOR P., PICARD A., LOCHER F.

BURRELL Q.L.
The 80/20 rule : Library lore or statistical law ? / Quentin L. Burrell.

GARFIELD E.
The Multiple Meanings of Impact Factors.

SALAUN J.M., LAFOUGE T., BOUKACEM C.
Demand for scientific articles and citations: An example from the Institut de l’information scientifique et technique (France).
Scientométrics, 2000, 47, 3, 561-588.

SCALES P.A.
Citations analyses as indicators of the use of serials : a comparison of ranked title lists produced by citation counting and from use data.

SYNDICAT NATIONAL DE L’INDUSTRIE PHARMACEUTIQUE.
www.snip.fr (9 july 2002).
Figure 1: Distribution and adjustment of orders from INIST-CNRS in 1998

\[ y = -182.75 \ln(x) + 850.33 \]

\[ R^2 = 0.9423 \]

Figure 2: Distribution and adjustment of orders from INIST-CNRS in 1999

\[ y = -180.13 \ln(x) + 836.26 \]

\[ R^2 = 0.934 \]
Figure 3: Total numbers of orders of our European pharmaceutical journals sample. Data are issued from the INIST-CNRS for 1996, 1997 and 1998.

Figure 4: Correlation between 1998 orders of our European pharmaceutical journals sample and number of citations in JCR 1997; Data are issued from the INIST-CNRS and ISI.
Figure 5: Breakdown of the coverage of the 289 European pharmaceutical journals of our sample by the three leading bibliographic databases

Figure 6: Breakdown of the coverage of the 149 European pharmaceutical journals ordered from INIST-CNRS by the three leading bibliographic databases

Figure 7: Average of orders for European pharmaceutical journals as a function of indexation in databases
Table I: Comparison “ordered from INIST-CNRS indexed by ISI”

<table>
<thead>
<tr>
<th></th>
<th>Indexed by ISI</th>
<th>Not indexed by ISI</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ordered from INIST-CNRS</td>
<td>60</td>
<td>89</td>
<td>149</td>
</tr>
<tr>
<td>Not ordered from</td>
<td>0</td>
<td>140</td>
<td>140</td>
</tr>
<tr>
<td>INIST-CNRS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>60</td>
<td>229</td>
<td>289</td>
</tr>
</tbody>
</table>

Table II: Average orders in 1998 for all of the journals ordered from INIST as a function of numbers of indexations in bibliographic databases

<table>
<thead>
<tr>
<th>Number of Indexations in databases</th>
<th>Journals Total 149</th>
<th>Average orders</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>18</td>
<td>27.8</td>
</tr>
<tr>
<td>1</td>
<td>22</td>
<td>59.3</td>
</tr>
<tr>
<td>2</td>
<td>19</td>
<td>39.2</td>
</tr>
<tr>
<td>3</td>
<td>25</td>
<td>44.2</td>
</tr>
<tr>
<td>4</td>
<td>22</td>
<td>67.7</td>
</tr>
<tr>
<td>5</td>
<td>24</td>
<td>223.2</td>
</tr>
<tr>
<td>6</td>
<td>19</td>
<td>319.7</td>
</tr>
</tbody>
</table>
### Appendix 1
Main characteristics of the 60 European pharmaceutical journals analysed by ISI and arranged by number of orders

<table>
<thead>
<tr>
<th>N°</th>
<th>ISSN</th>
<th>Title of journal</th>
<th>1998 Orders</th>
<th>1997 Citations</th>
<th>NB BIBLIO DB</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>0378-5173</td>
<td>INTERNATIONAL JOURNAL OF PHARMACEUTICS</td>
<td>1082</td>
<td>4347</td>
<td>6</td>
</tr>
<tr>
<td>2</td>
<td>0006-2952</td>
<td>BIOCHEMICAL PHARMACOLOGY</td>
<td>854</td>
<td>19121</td>
<td>5</td>
</tr>
<tr>
<td>3</td>
<td>0014-2999</td>
<td>EUROPEAN JOURNAL OF PHARMACOLOGY</td>
<td>715</td>
<td>26224</td>
<td>5</td>
</tr>
<tr>
<td>4</td>
<td>0012-6667</td>
<td>DRUGS</td>
<td>621</td>
<td>5914</td>
<td>6</td>
</tr>
<tr>
<td>5</td>
<td>0007-1188</td>
<td>BRITISH JOURNAL OF PHARMACOLOGY</td>
<td>601</td>
<td>23729</td>
<td>6</td>
</tr>
<tr>
<td>6</td>
<td>0031-6970</td>
<td>EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY</td>
<td>518</td>
<td>4028</td>
<td>5</td>
</tr>
<tr>
<td>7</td>
<td>0306-5251</td>
<td>BRITISH JOURNAL OF CLINICAL PHARMACOLOGY</td>
<td>516</td>
<td>5816</td>
<td>5</td>
</tr>
<tr>
<td>8</td>
<td>0004-4172</td>
<td>ARZNEIMITTEL-FORSCHUNG (DRUG RESEARCH)</td>
<td>504</td>
<td>3173</td>
<td>6</td>
</tr>
<tr>
<td>9</td>
<td>0022-3573</td>
<td>JOURNAL OF PHARMACY AND PHARMACOLOGY</td>
<td>502</td>
<td>4088</td>
<td>6</td>
</tr>
<tr>
<td>10</td>
<td>0269-2813</td>
<td>ALIMENTARY PHARMACOLOGY AND THERAPEUTICS</td>
<td>499</td>
<td>1950</td>
<td>4</td>
</tr>
<tr>
<td>11</td>
<td>0031-7144</td>
<td>PHARMACIE (DIE)</td>
<td>461</td>
<td>1311</td>
<td>6</td>
</tr>
<tr>
<td>12</td>
<td>0305-7453</td>
<td>JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY</td>
<td>428</td>
<td>6633</td>
<td>1</td>
</tr>
<tr>
<td>13</td>
<td>0731-7085</td>
<td>JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS</td>
<td>413</td>
<td>1724</td>
<td>6</td>
</tr>
<tr>
<td>14</td>
<td>0033-3158</td>
<td>PSYCHOPHARMACOLOGY (BERLIN, GERMANY)</td>
<td>373</td>
<td>12812</td>
<td>5</td>
</tr>
<tr>
<td>15</td>
<td>0163-7258</td>
<td>PHARMACOLOGY AND THERAPEUTICS</td>
<td>351</td>
<td>4116</td>
<td>6</td>
</tr>
<tr>
<td>16</td>
<td>0169-409X</td>
<td>ADVANCED DRUG DELIVERY REVIEWS</td>
<td>339</td>
<td>857</td>
<td>3</td>
</tr>
<tr>
<td>17</td>
<td>0040-5957</td>
<td>THERAPIE</td>
<td>338</td>
<td>435</td>
<td>6</td>
</tr>
<tr>
<td>18</td>
<td>0306-3623</td>
<td>GENERAL PHARMACOLOGY</td>
<td>287</td>
<td>1875</td>
<td>5</td>
</tr>
<tr>
<td>19</td>
<td>0344-5704</td>
<td>CANCER CHEMOTHERAPY AND PHARMACOLOGY</td>
<td>260</td>
<td>2909</td>
<td>4</td>
</tr>
<tr>
<td>20</td>
<td>0028-1298</td>
<td>NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY</td>
<td>250</td>
<td>6375</td>
<td>5</td>
</tr>
<tr>
<td>21</td>
<td>0028-3908</td>
<td>NEUROPHARMACOLOGY</td>
<td>234</td>
<td>6691</td>
<td>6</td>
</tr>
<tr>
<td>22</td>
<td>0268-1315</td>
<td>INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY</td>
<td>234</td>
<td>1295</td>
<td>2</td>
</tr>
</tbody>
</table>

3 NB BIBLIO DB: number of bibliographic databases analysing the journal.
<table>
<thead>
<tr>
<th>No.</th>
<th>Code</th>
<th>Journal Title</th>
<th>Volume</th>
<th>Pages</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>23</td>
<td>1043-6618</td>
<td>PHARMACOLOGICAL RESEARCH</td>
<td>218</td>
<td>666</td>
<td>5</td>
</tr>
<tr>
<td>24</td>
<td>0378-8741</td>
<td>JOURNAL OF ETHNOPHARMACOLOGY</td>
<td>209</td>
<td>805</td>
<td>6</td>
</tr>
<tr>
<td>25</td>
<td>0365-6233</td>
<td>ARCHIV DER PHARMAZIE</td>
<td>202</td>
<td>907</td>
<td>6</td>
</tr>
<tr>
<td>26</td>
<td>0901-9928</td>
<td>PHARMACOLOGY AND TOXICOLOGY</td>
<td>184</td>
<td>1710</td>
<td>5</td>
</tr>
<tr>
<td>27</td>
<td>0955-8810</td>
<td>BEHAVIOURAL PHARMACOLOGY</td>
<td>177</td>
<td>1101</td>
<td>1</td>
</tr>
<tr>
<td>28</td>
<td>0959-4973</td>
<td>ANTIcancer drugs</td>
<td>172</td>
<td>819</td>
<td>3</td>
</tr>
<tr>
<td>29</td>
<td>0031-6865</td>
<td>PHARMACEUTICA ACTA HELVETIAE</td>
<td>166</td>
<td></td>
<td>4</td>
</tr>
<tr>
<td>30</td>
<td>0261-2048</td>
<td>JOURNAL OF MICROENCAPSULATION</td>
<td>166</td>
<td></td>
<td>5</td>
</tr>
<tr>
<td>31</td>
<td>0142-2782</td>
<td>BIOPHARMACEUTICS AND DRUG DISPOSITION</td>
<td>165</td>
<td>540</td>
<td>5</td>
</tr>
<tr>
<td>32</td>
<td>0379-0355</td>
<td>METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY</td>
<td>160</td>
<td>538</td>
<td>5</td>
</tr>
<tr>
<td>33</td>
<td>0176-3679</td>
<td>PHARMACOPSYCHIATRY</td>
<td>160</td>
<td>935</td>
<td>4</td>
</tr>
<tr>
<td>34</td>
<td>1011-0283</td>
<td>SKIN PHARMACOLOGY</td>
<td>153</td>
<td>379</td>
<td>3</td>
</tr>
<tr>
<td>35</td>
<td>0031-7012</td>
<td>PHARMACOLOGY</td>
<td>147</td>
<td>1237</td>
<td>5</td>
</tr>
<tr>
<td>36</td>
<td>0278-5846</td>
<td>PROGRESS IN NEURO-PSYCHOPHARMACOLOGY AND BIOLOGICAL PSYCHIATRY</td>
<td>143</td>
<td>1192</td>
<td>5</td>
</tr>
<tr>
<td>37</td>
<td>0378-7966</td>
<td>EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS</td>
<td>138</td>
<td>411</td>
<td>6</td>
</tr>
<tr>
<td>38</td>
<td>0014-827X</td>
<td>FARMACO</td>
<td>136</td>
<td>555</td>
<td>6</td>
</tr>
<tr>
<td>39</td>
<td>0165-6147</td>
<td>TRENDS IN PHARMACOLOGICAL SCIENCES</td>
<td>134</td>
<td>8842</td>
<td>4</td>
</tr>
<tr>
<td>40</td>
<td>0867-5910</td>
<td>JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY</td>
<td>134</td>
<td>228</td>
<td>1</td>
</tr>
<tr>
<td>41</td>
<td>0009-3157</td>
<td>CHEMOTHERAPY</td>
<td>128</td>
<td>821</td>
<td>5</td>
</tr>
<tr>
<td>42</td>
<td>0960-314X</td>
<td>PHARMACOGENETICS</td>
<td>128</td>
<td>1671</td>
<td>3</td>
</tr>
<tr>
<td>43</td>
<td>0928-1231</td>
<td>PHARMACY WORLD &amp; SCIENCE</td>
<td>120</td>
<td>107</td>
<td>1</td>
</tr>
<tr>
<td>44</td>
<td>0269-4727</td>
<td>JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS</td>
<td>117</td>
<td>199</td>
<td>6</td>
</tr>
<tr>
<td>45</td>
<td>0269-8811</td>
<td>JOURNAL OF PSYCHOPHARMACOLOGY</td>
<td>113</td>
<td>633</td>
<td>1</td>
</tr>
<tr>
<td>46</td>
<td>0003-9780</td>
<td>ARCHIVES INTERNATIONALES DE PHARMACODYNAMIE ET DE THERAPIE</td>
<td>109</td>
<td>1547</td>
<td>5</td>
</tr>
<tr>
<td>47</td>
<td>0767-3981</td>
<td>FUNDAMENTAL AND CLINICAL PHARMACOLOGY</td>
<td>108</td>
<td>567</td>
<td>5</td>
</tr>
<tr>
<td>48</td>
<td>0223-5234</td>
<td>EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY</td>
<td>103</td>
<td>1071</td>
<td>1</td>
</tr>
<tr>
<td>49</td>
<td>0192-0561</td>
<td>INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY</td>
<td>93</td>
<td>1399</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS</td>
<td></td>
<td>90</td>
<td>854</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>------------------------------------------------------</td>
<td>---</td>
<td>----</td>
<td>----</td>
</tr>
<tr>
<td>51</td>
<td>0753-3322</td>
<td>BIOMEDECINE AND PHARMACOTHERAPY</td>
<td></td>
<td>86</td>
<td>458</td>
</tr>
<tr>
<td>52</td>
<td>1157-1497</td>
<td>STP PHARMA PRATIQUES</td>
<td></td>
<td>73</td>
<td>183</td>
</tr>
<tr>
<td>53</td>
<td>0885-6222</td>
<td>HUMAN PSYCHOPHARMACOLOGY</td>
<td></td>
<td>70</td>
<td>347</td>
</tr>
<tr>
<td>54</td>
<td>0251-1649</td>
<td>INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY RESEARCH</td>
<td></td>
<td>69</td>
<td></td>
</tr>
<tr>
<td>55</td>
<td>0931-8771</td>
<td>QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS</td>
<td></td>
<td>53</td>
<td>461</td>
</tr>
<tr>
<td>56</td>
<td>0378-0619</td>
<td>ACTA THERAPEUTICA</td>
<td></td>
<td>30</td>
<td>73</td>
</tr>
<tr>
<td>57</td>
<td>0952-0600</td>
<td>PULMONARY PHARMACOLOGY</td>
<td></td>
<td>30</td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>0144-1795</td>
<td>JOURNAL OF AUTONOMIC PHARMACOLOGY</td>
<td></td>
<td>26</td>
<td>485</td>
</tr>
<tr>
<td>59</td>
<td>0379-8305</td>
<td>DEVELOPMENTAL PHARMACOLOGY AND THERAPEUTICS</td>
<td></td>
<td>24</td>
<td></td>
</tr>
<tr>
<td>60</td>
<td>0736-0118</td>
<td>MEDICAL ONCOLOGY AND TUMOR PHARMACOTHERAPY</td>
<td></td>
<td>4</td>
<td>183</td>
</tr>
</tbody>
</table>